Regeneron (REGN) Stock
Key stats
- Market cap
- $93.40B
- Price / Earnings ratio
- 20.0x
- EPS (TTM)
- $47.01
- Volume
- Loading
- 52-week high
- $991.73
- 52-week low
- $591.52
- Dividend yield
- 0.41%
- Dividend amount (latest)
- $0.94
- EPS vs analyst estimate
- +33.8%Q3 FY25 · $11.83 vs $8.84
Source: third-party data provider, as of November 7, 2026
EPS estimate: analyst consensus
Compare with REGN
Recent news

Regeneron: 3 Key Takeaways for Long-Term Investors
Regeneron: 3 Key Takeaways for Long-Term Investors
REGN

REGN Q3 Earnings Beat on Dupixent Profits & Eylea HD Growth, Stock Up
REGN Q3 Earnings Beat on Dupixent Profits & Eylea HD Growth, Stock Up
REGN

What Regeneron Pharmaceuticals (REGN) Said on Its Q3 Earnings Call
What Regeneron Pharmaceuticals (REGN) Said on Its Q3 Earnings Call
REGN

Regeneron Surges 13.55%: Here's What It Means for Your Health Care ETFs
Regeneron Surges 13.55%: Here's What It Means for Your Health Care ETFs
REGN
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 62.93
- MACD 12/26/9
- 40.65
- EMA 9 of MACD
- 26.75
- MACD histogram
- 13.90
- SMA 50
- $802.45
- Price above SMA 50
- EMA 50
- $807.91
- Price above EMA 50
- SMA 200
- $741.59
- Price above SMA 200
- EMA 200
- $758.06
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 5, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 20 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $9.41 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Regeneron: 3 Key Takeaways for Long-Term Investors
Regeneron: 3 Key Takeaways for Long-Term Investors
REGN

REGN Q3 Earnings Beat on Dupixent Profits & Eylea HD Growth, Stock Up
REGN Q3 Earnings Beat on Dupixent Profits & Eylea HD Growth, Stock Up
REGN

What Regeneron Pharmaceuticals (REGN) Said on Its Q3 Earnings Call
What Regeneron Pharmaceuticals (REGN) Said on Its Q3 Earnings Call
REGN

Regeneron Surges 13.55%: Here's What It Means for Your Health Care ETFs
Regeneron Surges 13.55%: Here's What It Means for Your Health Care ETFs
REGN

Regeneron Surges 12% as Sanofi Dupixent Windfall and Eylea HD Power Earnings Beat; Moderna Slides 2%, Merck Edges Higher, Pfizer Ticks Up
Regeneron Surges 12% as Sanofi Dupixent Windfall and Eylea HD Power Earnings Beat; Moderna Slides 2%, Merck Edges Higher, Pfizer Ticks Up
REGN

Regeneron (REGN) Reports Q3 Earnings: What Key Metrics Have to Say
Regeneron (REGN) Reports Q3 Earnings: What Key Metrics Have to Say
REGN

Regeneron, Sanofi Surge As Dupixent Wallops Sales Forecasts
Regeneron, Sanofi Surge As Dupixent Wallops Sales Forecasts
REGN

Regeneron (REGN) Q3 Earnings and Revenues Beat Estimates
Regeneron (REGN) Q3 Earnings and Revenues Beat Estimates
REGN

REGN Stock Hits 2-Year Highs Pre-Market: CFO Says Regeneron Is Positioned To Deliver One Of ‘Strongest Years Ever’ After Q3 Earnings Beat
REGN Stock Hits 2-Year Highs Pre-Market: CFO Says Regeneron Is Positioned To Deliver One Of ‘Strongest Years Ever’ After Q3 Earnings Beat
REGN

Here's Why Regeneron (REGN) is a Strong Value Stock
Here's Why Regeneron (REGN) is a Strong Value Stock
REGN
News tone: automated (AI) classification of the article's content, not a price prediction.
About Regeneron
Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to eight FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye disease, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, infectious diseases, pain and rare diseases.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Leonard S. Schleifer M.D., Ph.D. | Co-Founder, President, CEO & Co-Chairman | 1953 |
| Dr. George D. Yancopoulos M.D., Ph.D. | Co-Founder, President, Chief Scientific Officer & Co-Chairman | 1960 |
| Mr. Christopher R. Fenimore CPA | Executive VP of Finance & CFO | 1971 |
| Mr. Joseph J. LaRosa J.D. | Executive VP, General Counsel & Secretary | 1959 |
| Dr. Andrew J. Murphy Ph.D. | Executive VP of Research & Co-Chief Scientific Officer | 1958 |
| Mr. Daniel P. Van Plew | Executive VP and GM of Industrial Operations & Product Supply | 1973 |
| Mr. Rajesh Ahuja | Senior Vice President of Quality Assurance & Operations | — |
| Mr. Ryan Steinberger | Executive VP, Chief Digital & Technology Officer | — |
| Mr. Ryan Crowe | Senior Vice President of Investor Relations & Strategic Analysis | — |
| Ms. Melissa Lozner | Senior VP & Chief Compliance Officer | — |
Fundamentals
Valuation
Profitability
Trading
Dividend
Source: third-party data provider, as of November 7, 2026
Technical indicators
- RSI 14
- 62.93
- MACD 12/26/9
- 40.65
- EMA 9 of MACD
- 26.75
- MACD histogram
- 13.90
- SMA 50
- $802.45
- Price above SMA 50
- EMA 50
- $807.91
- Price above EMA 50
- SMA 200
- $741.59
- Price above SMA 200
- EMA 200
- $758.06
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 5, 2026. Technical data, not a recommendation.
Analyst views
20 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $812.00
- Average
- $955.85
- High
- $1,175.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +2.2 | +0.1 | ||||||||||
| 2022 | -3.0 | +0.8 | +15.1 | -5.1 | +2.0 | -10.3 | -2.3 | +0.8 | +14.7 | +1.9 | -1.1 | -5.2 |
| 2023 | +5.3 | +0.3 | +6.6 | -3.0 | -8.8 | -1.7 | +3.3 | +11.8 | -1.0 | -4.7 | +4.1 | +7.8 |
| 2024 | +4.2 | +0.9 | -2.1 | -8.1 | +8.5 | +6.2 | +2.1 | +8.4 | -10.1 | -19.9 | -11.1 | -6.6 |
| 2025 | -5.9 | +4.8 | -7.4 | -3.0 | -16.9 | +7.0 | +2.0 | +3.9 | -2.7 | +8.6 | +21.5 | +2.9 |
| 2026 | -4.5 | +3.5 | -2.3 | -9.0 | -12.4 | +3.8 | +22.1 | +5.2 | -8.0 | +26.3 | -3.2 |



